# CURRICULUM VITAE

**SANDIP K. MUKHERJEE, M.D., F.A.C.C.**

**Yale School of Medicine / Section of Cardiovascular Medicine**

Email: sandip.mukherjee@yale.edu W: 203-789-2272 C: 203-671-1816

# EDUCATION

1992-1995 **Fellowship in Cardiovascular Medicine Yale University School of Medicine** New Haven, Connecticut

## (Level III Advanced Fellowship in Echocardiography: 1994-95 First Cardiovascular Echocardiography Fellow at Yale)

1991-1992 **Chief Medical Resident**

## Yale University School of Medicine

New Haven, Connecticut

## 1988-1991 Internship & Residency in Internal Medicine

**Yale-New Haven Hospital**

**Yale University School of Medicine**

New Haven, Connecticut

1984-1988 **M.D.**

## Texas Tech University School of Medicine

Lubbock, Texas

*1978-1982* **Bachelor of Science (Biology) *(Beta Beta Beta)***

## Texas A&M University

College Station, Texas

# PROFESSIONAL POSITIONS

2019 - Present **Executive Medical Director**

## Office of the Chief Medical Officer, Yale New Haven Hospital

2019 - Present **Chief, Complex and Executive Health**

## Yale New Haven Health System

2018 - Present **Associate Professor of Clinical Medicine**

## Yale School of Medicine (Cardiovascular Medicine)

2010 - Present **Cardiac Director,**

## The Aortic Institute at Yale New Haven

2013 – Present **Associate Editor, Journal: *AORTA***

1999 - Present **Senior Editorial Committee: *The Medical Letter***

2006 - Present **Fellow, Pearson College, *Yale University***

|  |  |
| --- | --- |
| 2015- 2019 | **Medical Director, Physician Liaison Services,****Office of the Chief Medical Officer, Yale New Haven Hospital** |
| 2003- 2018 | **Associate Clinical Professor of Medicine,*****Yale School of Medicine*** |
| 2000- 2013 | **Co**-**Director: Clinical Research Trials Center, Cardiology Associates of New Haven, P.C.** |
| 2005-2007 | **Vice President, *South Asian Society of Atherosclerosis*** |
| 1996-2003 | **Assistant Clinical Professor of Medicine,*****Yale School of Medicine*** |
| 1997-1999 | **Yale Clinical Trials Consortium** |
| 1997-1999 | **Editorial Fellow: *The Medical Letter*** |
| 1996-2006 | **Editorial Consultant: *Catheterization and Cardiovascular Interventions*** |
| 1995-1996 | **Clinical Instructor of Medicine*****Yale University School of Medicine*** |

# HONORS AND AWARDS

2010-2020 ***Top Doctors : Connecticut Magazine***

### (voted for inclusion by physician peers for the past 10 years)

2013, 2015 ***New Haven Magazine – Best Doctors (2013, 2015)***

2002-2006 ***Yale School of Medicine Society of Distinguished Teachers***

2002-2020 ***Top Doctors List (Guide to Top Doctors*)**

2002-2006 ***Who’s Who in Medicine and Healthcare***

### 2001 Nominee: Departmental Award for Excellence in Teaching Ambulatory Internal Medicine to Medical Students (Yale Medical School)

1996 ***Benedict R. Harris Award***

Presented annually by the First Year Residents of Yale-New Haven Hospital to the Physician who has contributed the most to the teaching of the House Staff

1993 ***Hugh L. Dwyer Award***

Presented annually to a senior resident in Internal Medicine, Neurology, or Dermatology at Yale whose clinical practice emulates the distinguished characteristics exemplified by Hugh Dwyer, M.D.

### 1992 Betsy Winters House Staff Award

Presented annually by the graduating class of Yale Medical School to the member of the House Staff of Yale Medical Center who made the most significant contribution to their education

### 1992 Who’s Who Among Rising Young Americans

1991 ***Stephen R. Shell Award***

Presented annually to the graduating member of the Yale Medical Housestaff who in the opinion of his or her peers embodies the esteemed values of Stephen R. Shell, M.D.

### 1988 Merck Award for Academic Excellence

1978 ***National Biological Honor Society (Beta Beta Beta)***

**CLINICAL INVESTIGATION**

**(Clinical Trials Director – Primary Investigative Site)**

2012 **Primary Investigator: REDUCE-IT Protocol AMR-01-01-0019** *A Multi-Center, Prospective, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)*

2012 **Primary Investigator: Phase IV Pradaxa Protocol 1160.128** *A prospective, open label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q.a.m. and taking*

*Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150 mg*

*b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)*

2009-2012 **Sub-Investigator: SOLID TIMI 52 Protocol SB-480848-033** *A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Cardiovascular Events (MACE)*

2009-2012 **Sub-Investigator: DAL-OUTCOMES Protocol NC20971C**

*A Phase III, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)*

## 2008-2010 Primary Investigator: ROCKET AF Protocol JNJ39039039AFL3001

*A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel- Group, Multi-Center, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban(BAY-59-7939) with Adjusted Dose Oral Warfarin for the Prevention of Stroke and*

*Non-Central Nervous System Stystemic Embolism in Subjects with Non- Valvular Atrial Fibrillation*

## 2008-2012 Primary Investigator: DEFINE Protocol 01900

*A 76 Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients with Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease*

## 2007-2011 Primary Investigator: IMPROVE-IT Protocol P04103

*A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin vs Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome*

2006-2010 **Primary Investigator:** (**NIH-funded study) National Multicenter Study: TELE-HF YALE Heart *Failure Telemonitoring Study***

2009-2011 **Primary Investigator: RE-LYable STUDY Protocol 1160.71** *A Long Term Multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a*

*cluster randomized trial to assess the effect of a knowledge translation intervention on patient outcomes*

2007-2009 **Primary Investigator: RE-LY STUDY Protocol 1160.26** *Randomized Evaluation of Long term anticoagulant therapy comparing the efficacy and safety of two blinded doses of dabigatran Etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation*

2006-2009 **Primary Investigator: (NHLBI-funded trial): COPES II** *A Multi-center Observational Study Funded by the NHLBI on depressive Symptoms in Hospitalized ACS Patients*

2006-2008 **Primary Investigator: CRESCENDO Study**

*Randomized, multi-national, multicenter, double-blind, placebo- controlled, two-arm parallel group trial of rimonabant 20mg QD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors*

## 2005-2006 Primary Investigator: Esperion Protocol 588-007

*A Phase II Randomized, Double-Blind, Placebo- Controlled, Multicenter, Pharmacokinetic, Pharmacodynamic And Tolerability Study Of ETC- 588 In Patients With Stable Atherosclerosis*

2003-2005 **Primary Investigator: (NHLBI-funded trial ): COPES** *A Multi-center Observational Study Funded by the NHLBI on depressive Symptoms in Hospitalized ACS Patients*

## 2004-2007 Primary Investigator: ILLUMINATE Trial

*Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of the Fixed Combination torcetrapib/atorvastatin, Administered Orally, Once Daily , Compared with atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents*

## 2004-2009 Sub-Investigator: ACTIVE Protocol EFC4912

*A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, with Factorial Evaluation of irbesartan, for the Preventionof Vascular events, in patients with Atrial Fibrillation*

2004-2009 **Primary Investigator: ACCOMPLISH Trial**

*A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled Trial to Compare the Effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension*

## 2003 Primary Investigator: EASE Protocol 040-01

*A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy of Ezetimibe 10mg/day When Added to Ongoing Therapy Alone, in Patients with Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL- Cholesterol Level*

2003-2004 **Primary Investigator: IRIS Study**

*A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvaststin in the Treatment of Hypercholesterolemia in South Asian Subjects*

## 2002 Primary Investigator: Ezetimibe Protocol 025

*A Multicenter, Double-Blind, Randomized, Parallel Group, 28-week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co-administration Versus Atorvastatin in Patients with Hypercholesterolemia*

## 2002 Primary Investigator: NASDAC Trial

*A Multicenter Eight Week Double Blind Assessment Comparing the Efficacy and Safety of Simvastatin 80mg/day Versus Atorvastatin 80mg/day in Patients with Hypercholesterolemia*

*2001-2002* **Primary Investigator: CHESS Trial**

*A Multicenter, Double-Blind, Randomized, Parallel, 28-Week Study to Evaluate the Efficacy and Safety of Simvastatin 80mg/day Versus Atorvastatin 80mg/day in Patients with Hypercholesterolemia*

## 2001-2002 Primary Investigator: A to Z Trial (TIMI-21)

*A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment with Simvastatin 40mg Daily for 30 days, followed by Simvastatin 80mg daily, thereafter in Tirofiban-Treated Acute Coronary syndrome Patients who have been Randomized to receive Enoxaparin or Unfractionated Heparin in conjunction with Aspirin*

1999-2001 **Primary Investigator: PRINCE**

*Pravastatin Inflammation/ CRP Evaluation*

## 1999-2000 Primary Investigator: Prospective Observational Study of Simvastatin & other Statins in High Risk Patients

1998-2000 **Primary Investigator: CHALLENGE Trial**

1998-2000 **Associate Investigator: SYMPHONY TRIAL**

*Sirafiban vs. Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes*

1997-2002 **Sub-Investigator: MIRACL Trial**

*Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering*

1996-2003 **Primary Investigator/Clinical Steering Committee/ Co- Director: ENRICHD Trial [NIH/NHLBI Funded Trial]** *Enhanced Recovery in Coronary Artery Disease*

# PUBLICATIONS

1. Elefteriades JA, **Mukherjee SK**, Mojibian H. Discrepancies in Measurement of the Thoracic Aorta. ***J Am Coll Cardiol*** 2020; 76:201-17.
	* This paper was cited as “**JACC Review Topic of the Week” (July 14, 2020)**
2. Wu J, Zafar MA, Li Y, Saeyeldin A, Huang Y, Zhao R, Qui J, Tanweer M, Abdelbaky M, Gryaznov A, Buntin J, Ziganshin B, **Mukherjee SK,** Rizzo J, Yu C, Elefteriades JA. Ascending Aortic Length and Risk of Aortic Adverse Events: The Neglected Dimension: Ascending Aortic Length Enhances Risk Assessment for Aortic Dissection**. *J Am Coll* Cardiol** 2019;74:1883-94.

### This paper was cited as “Editor-in-Chief’s Top Picks From 2019” (Top 100 papers of 2019) (J Am Coll Cardiol Vol.74, No 7, 2020 – our abstract is on pp 830-831)

1. Zafar, MA, Chen, JF, Wu, J, Li,Y, Papanikolaou D, Abdelbaky, M, Vinholo, Vinholo TF, Rizzo JA, Rizzo J, Ziganshin BA, **Mukherjee SK,** Elefteriades JE. Natural History of Descending and Thoracoabdominal Aortic Aneurysms. ***J Thoracic and Cardiovascular Surg****.* 2019 Nov 11;S0022-5223 (19) 32517-6.
2. Olson K, Sinsky C, Rinne S, Long T, Vendor R, **Mukherjee S**, Bennick M, Linzer M. Cross Sectional Survey of Workplace Stressors Associated with Physician Burnout Measured by the Mini-Z and the Maslach Burnout Inventory. ***Stress and Health****.* (2019). pp 1-19.
3. Bin Mahmood SU, Velasques CA, Zafar, MA, Saeyeldin AA, Brownstein AJ, Ziganshin BA, Elefteriades, JA, **Mukherjee, SK**. Medical Management of Aortic Disease in Marfan Syndrome. ***Annals of Cardiothoracic Thoracic Surgery*.** 2017; 6:654-661.
4. Percy, AG, **Mukherjee, SK**, Ziganshin, B, Elefteriades, JE. **Book chapter: Current Status of Medical Therapy of Thoracic Aortic Aneurysm and Dissection.** (Chapter 22; Nov 2017)
5. Ziganshin BA, **Mukherjee SK**, Elefteriades JA. Medical Therapies to Prevent Aortic Aneurysm in Marfan Syndrome. Correspondence: ***N Engl J Med*** 2015;372(10), pp 977-981.
6. Pillai AT, Schoenhagen P, Subrahmanyan L, **Mukherjee SK**, McNamara RL, Elefteriades J, Svensson LG. Aortic Dissection Associated with Penetration of a Spinal Pedicle Screw: A Case Report and Review of the Literature. ***J Card Surg*** 2014;29:377-381.
7. Chun AS, Elefteriades JA, **Mukherjee SK.** Medical Treatment for Thoracic Aortic Aneurysm

-Much More Work to be Done. ***Progress in Cardiovascular Disease*: Special Edition on Aortic Aneurysms.** July 2013.

1. Chun AS, Elefteriades JA, **Mukherjee SK.** Do B-Blockers Really Work for Prevention of Aortic Aneurysms: Time for Reassessment? ***AORTA*** 2013. Vol 1, Issue 1.
2. Hung A, Zafar M, **Mukherjee S,** Tranquilli M, Scoutt LM, Elefteriades JA. Carotid Intima Media Thickness Provides Evidence that Ascending Aortic Aneurysm Protects Against systemic atherosclerosis. ***Cardiology***. 2012; 123(2) 71-7.
3. **Mukherjee SK**. HIV, Dyslipidemia, and Premature Cardiovascular Disease. ***UpToDate****.*

2006.

1. R Scandrett, **SK Mukherjee.** *New Frontiers in Women’s Cardiovascular Health*. **World Heart Journal**. 2006.
2. A Mani, **SK Mukherjee.** Finding a Needle in a Haystack – Unveiling the Genetic Basis for Coronary Artery Disease among Asian- Indians. In*:* ***Diabetes (Type 2) in South Asians: Epidemiology, Risk factors and Prevention****.* 2006.
3. **SK Mukherjee**, D Lao. The South Asian Paradox – From Prevention to Intervention. In: ***Coronary Artery Disease: Risk Promoters, Pathophysiology and Prevention*.** Jaypee Brothers Medical Publishers: New Delhi, India, 2005.
4. **SK Mukherjee**, M Kosiborod. Cardiovascular Drugs in the Intensive Care Unit. Drugs of Choice from the Medical Letter. ***The Medical Letter****. Fifteenth Edition 2002*
5. TL Skaer, DA Sclar, MA Evans, **SK Mukherjee,** LM Robinson, HMG-CoA Reductase Inhibitors in Secondary Prevention of CHD: Comparison of Expense Per Year of Life Gained. ***American Journal of Cardiology****.* 2001
6. **SK Mukherjee**. Identifying the Target Population in Acute Coronary Syndromes.

***Connecticut Cardiologist*** (CT Chapter / American College of Cardiology) 2000; 6(1):4-5.

1. **SK Mukherjee**. Drugs for Chronic Heart Failure. ***The Medical Letter*** 1999;41:12-14
2. S. Aronin, **SK Mukherjee**, JC West, EL Cooney. Review of Pneumococcal Endocarditis in Adults in the Penicillin Era. ***Clinical Infectious Diseases*** *1998;26 165-171.*
3. **SK Mukherjee**. Clopidogrel for Reduction of Atherosclerotic Events. ***The Medical Letter****.* 1998; 40:59-60.
4. **SK Mukherjee**. Mibefradil- A New Calcium-Channel Blocker. ***The Medical Letter***

*1997; 103-105.*

1. S. Raza, **SK Mukherjee**, P Danias, JI Abraham, KJ Johnson, MJ Sands, MS Werner, and DI Silverman. Hemodynamically Significant Extrinsic Left Atrial Compression from Gastric Structures in the Mediastinum . ***Annals of Internal Medicine*** *1995;123:114-116.*
2. **SK Mukherjee**, CC Jaffe. Left Ventricular Mass Estimation by Echocardiography. Is it Clinically Useful? ***Echocardiography*** *1995, 12(2): 185-193.*
3. **SK Mukherjee** (Contributing Author. **The Functional Heart: Echocardiography of Ventricular Contraction (CD ROM),** 1995.
4. **SK Mukherjee** and HM Krumholz. Cholesterol in the Elderly. ***Medical Outlook for Cardiologists.*** *1995; Vol. 11, No. 1.*
5. **SK Mukherjee** and HM Krumholz. Secondary Prevention after Acute Myocardial Infarction in the Elderly. ***Cardiology in the Elderly*** *1994, 2:295-300.*
6. **SK Mukherjee.** Should Humanities Be Taught? *Yale Journal of Biology and Medicine.*

1992;65(3): 158-159.

# ABSTRACTS / POSTERS

Hsaio A, Kashyap N, Khokar B, **Mukherjee S**, Cofrin B, Caisse B, Christian J, Obrien W, Richter B, Sicoli P, Torre C, Travers J, Stanton G, Stump L. Information strategies technologies to help mitigate physician burnout. Healthcare Information and Management Systems Society (HIMSS). Poster. 2019.

Zafar MA, Chen JF, Wu J, Li Y, Charilaou P, Papanikolaou D, Imran M, Abdelbaky M, Vinholo T, Saeyyeldin A, Gryaznov A, Tanweer M, Mansour A, Jang S, Sebastian A, Elashwal M, Aldin A, Buntin J, Peters S, Rizzo J, Ziganshin B, Ziganshin B, **Mukherjee SK**, Elefteriades JE. Podium presentation at the AATS 99th Annual Meeting 2019. Toronto, ON, Canada, May 2, 2019. Natural history of descending thoracic and thoracoabdominal aortic aneurysms. American Association for Thoracic Surgery – Centennial Meeting. Poster presentation. May 2019.

Olson, K, Linzer, M, Rinne, **S, Mukherjee**, S, Bennick, M, Sinsky, C, Krumholz, H, Vender, R, Long, Comparing Practice Models and Workplace Stressors to Explain Burnout. Academy Health Annual Research Meeting. 2017.

Walaliyadda, R.H.Li, **SK Mukherjee.** *“Transient Left Bundle Branch Block Following Blunt Trauma to the Chest”.*

American College of Physicians (CT Chapter) 1997 (abstract).

S Anuras, **SK Mukherjee.** D Dunn, V Kulhrani, and JB Green. A New Family with Autosomal Dominant Transmitted Visceral Neuropathy. *Gastroenterology*. 1988;94: 10.

S Anuras, **SK Mukherjee.** D Dunn, and JB Green. Dumping Syndrome in a Family with Abnormal Gastrointestinal Motility. *Clinical Research. 1988;36: 13A.*

# BOARD CERTIFICATION

## 1991 Diplomate: American Board of Internal Medicine

1996-present **Diplomate: Cardiovascular Disease (Active)**

## (Recertified for 2016-2026 by American Board of Internal Medicine)

**MEDICAL LICENSURE**

**Connecticut Medical Licensure**: #031376 (Active) Issued 2/22/1991; valid to present time

# PRESENTATIONS

### 08/29/2019 Yale Medical Grand Rounds. Masone Foundation Endowed Lectureship. “New Frontiers in Thoracic Aortic Disease”

*03/14/2019* ***Danbury Hospital Medical Housestaff Conference: An Update on Thoracic Aortic Disease***

*08/03/2018* ***Greenwich Hospital Medical Grand Rounds: An Update on Thoracic Aortic Disease.***

*10/10/2017* ***European Association of Cardiothoracic Surgery. Vienna, Austria. “Aortic Catastrophes”.***

*10/19/2017* ***Jonathan Knights Society / 1826 Society. “The Future of Cardiology”***

*4/9/2016* ***5th Annual Interventional Yale CME Conference (Yale School of Medicine). “Frontiers in Thoracic Aortic Disease”***

*11/9/2014* ***Aortic Institute at Yale-New Haven Hospital*. *“****A Tale of Two Cusps”. 5/9/13* ***Yale Health Medical Grand Rounds****. Of Inuits, Indians and Italians. 5/7/13* ***Aortic Institute at Yale-New Haven Hospital***

*The Globalization of Coronary Artery Disease.*

*4/8/13* **CT Association of Physician Assistants**. *Five Top Cardiac Issues of 2012. 4/8/13* **CT Association of Physician Assistants**. *The Globalization of Coronary*

*Artery Disease.*

*4/26/06* ***Yale HIV Center – Yale Medical School.*** *HIV and Cardiovascular Prevention – The Metabolic Link.*

*4/20/06* ***Cornell Medical Center– NYU Hospital:*** *Of Inuits and Indians – The Global Cardiovascular Disease Burden*

11/18/2005 ***Dartmouth Medical Center*** Endocrinology Grand Rounds: “*The Rising Tide of Diabetes in Developing Nations”*

*11/10/2005* ***Yale Health Medical Grand Rounds.*** *“Cardiac Risk Prevention – Strategies that Work … And Some that Don’t”*

7/13/05 ***Yale Emergency Department Grand Rounds.*** *“Why King George Died”*

6/29/05 ***Yale Emergency Department Grand Rounds.*** *“New Treatment Strategies in Acute Coronary Syndrome”*

*5/14/05* ***Connecticut Association of Physicians of Indian Origin. “****The Rising tide of Metabolic Syndrome and Diabetes in South Indians”*

*5/4/05* ***Connecticut Association of Physicians Assistants.*** *“Women and Heart Disease – A 2005 Primer”*

*3/10/05* ***Yale Medical School* “***A Tale of Two Men – An Update on Coronary Prevention”*

*3/06/05* ***American College of Cardiology (American Association of Cardiologists of Indian Origin)*** *“The Alarming Rise of Coronary Artery Disease among South Asians – A Tidal Wave of Concern”*

*2/05/05* ***American Association of Physicians of Indian Origin****. “The South Asian Paradox”*

*12/09/04* ***Yale Health University Services Medical Rounds*** *“LDL: How Low is Too Low?”*

### 11/02/04 Yale New Haven Hospital Medical Center, Hospitalist Service

*“Cardiology Teaching Conference”*

*7/14/04* ***Yale Emergency Department Grand Rounds*** *“Acute Coronary Syndrome”*

*6/24/04* ***Yale Medical School.*** *“Cardiac Prevention”*

*3/30/04* ***American Association of Physician Specialists*** *“How To Prevent Heart Disease”*

*3/11/04* ***Yale Internal Medicine Housestaff Conference*** *“Of Indians, Inuits and Italians”*

09/27/2002 ***Hoffman Heart and Vascular Institute*** *“A New Paradigm Shift in Therapies of Non ST-Elevation Acute Coronary Syndrome”*

*09/21/2002* ***American Association of Physicians of Indian Origin (AAPI*):** *“The Indian Paradox”- Why Asian-Indians Have High Risk for Coronary Disease*

*09/12/2002* ***Yale University Medical Grand Rounds*** *Aortic Dissection: “Was it the Chicken or the Egg?”*

*09/10/2002* ***Yale University Health Sciences Center Grand Rounds.*** *“New Advances in the Treatment of Hypertension”*

*07/17/2002* ***Yale University Emergency Department*** *“New Advances in Acute Coronary Syndrome”*

*03/13/2002* ***University of Massachusetts Primary Care Symposia*:”** *Women and Heart Disease”*

*03/02/2002* ***Yale Medical School.*** *“Women and Heart Disease” 02/12/2002* ***Yale University Health Sciences Center Grand Rounds*.**

*“Comprehensive Risk Reduction for Coronary Disease”*

01/11/2001 ***Dartmouth College*** “*Upstream Use of GP IIB IIIA Inhibitor Therapy*”

11/02/2001 ***American College of Physicians (NY Chapter)*** *“Comprehensive Risk Reduction for Coronary Heart Disease”*

*10/12/2000* ***Yale Klatskin Firm Conference*** *“Thinking Outside the Box- New Developments in Atherosclerosis”*

*10/26/2000* ***New York Academy of Science* “***Use of GP IIB IIIA Agents in Acute Coronary Syndromes”*

*09/23/2000* ***24th Annual Yale Physician Assistant Board Review- Primary Care Conference.*** *“Current Therapeutic Approaches to Hypertension”*

### 08/30/2000 Yale University Cardiology Fellows Conference

*“New Paradigms in the Treatment of Acute Coronary Syndromes”*

### 07/19/2000 Yale University Emergency Department Conference

*“Update on Acute Coronary Syndromes”*

*05/07/2000* ***Connecticut Osteopathic Association***

*“Emerging Trends and New Sciences in the Management of Dyslipidemia”*

*05/05/2000* ***American College of Emergency Physicians. (8th International Conference on Emergency Medicine)*** *“Emergency Management of Acute Coronary Syndromes”*

*04/03/2000* ***Connecticut Academy of Physician Assistants*** *“Comprehensive Risk Reduction for CAD” “Update on Acute Coronary Syndromes”*

### 01/10/2000 Yale School of Medicine: Medical Housestaff Conference

*“New Paradigms in the Treatment of Acute Coronary Syndromes”*

### 01/07/2000 Yale School of Medicine: Cardiology Fellows Conference

*“Non-Traditional Risk Factors for CAD”*

*10/03/1999* ***Association of Nuclear Cardiologists***

*“New Pharmacological Treatment Paradigms for Acute Coronary Syndromes”*

*08/30/1999* ***Yale School of Medicine Cardiology Fellows Conference “****Stress Echocardiography”*

*08/17/1997* ***Yale Medical Grand Rounds***

*“Aneurysm Dissequant” (Aortic Dissection)*

*05/21/1997* ***American College of Physicians*** *(CT Chapter)*

*“Transient Left Bundle Branch Block Following Blunt Trauma to the Chest”*

*04/28/1995* ***Yale Cardiology Grand Rounds*** *“Stress Echocardiography” 04/30/1993* ***Yale Cardiology Grand Rounds***

*“Predicting Sudden Death After Myocardial Infarction:*

*Current Limitations and Future promises”*

*09/23/1992* ***National Academy of Arts and Sciences*** *(CT Chapter)*

*“Medical Care in the 90’s: Cost for the Patients; Anguish for the Physician”*

|  |  |
| --- | --- |
| *11/07/1991* | ***Yale Medical Grand Rounds****“Humanism in Medicine”* |
| *05/16/1988* | ***American Gastroenterological Association****“A New Family with Autosomal Dominant Visceral Neuropathy”* |
| *02/02/1988* | ***American Federation for Clinical Research****“Dumping Syndrome in a Family with Abnormal Gastrointestinal Motility”* |

# PROFESSIONAL MEMBERSHIPS / COMMITTEES

Member (Active) Physician Executive Council, Yale New Haven Hospital Member (Active) Joint Leadership Council, Yale New Haven Hospital Member (Active) Medical Leadership Council, Yale New Haven Hospital Member (Active) Medical Executive Committee, Yale New Haven Hospital Fellow (Active) American College of Cardiology

C0-Chair (Active) Medical Staff Engagement Committee, Yale New Haven Hospital

Member (Active) Committee on Part-Time Faculty Appointments & Promotions / Yale School of Medicine

Fellow (Active) Pearson College, Yale University

Board of Governors New Haven County Medical Association (Active) CME Co-Director Yale Aortic Institute Monthly Conferences (Active) Echo Reading Panel Yale Heart and Vascular Center (Active)

Yale Thesis Advisor Yale School of Medicine (for David Dupee, MD) (2016-2020) (Active)

Founder / Chair Aortic Institute Research Fellowship (2018-present):

Inaugural Fellow- Mohammad Zafar, MD (Active Research Fellowship)

Chair (Active) Yale New Haven Executive Health Program

(Chair collaborative effort with Office of Strategy Management (YNHHS) and Yale School of Medicine to help create a world-class Yale New Haven Executive Health Program (at Greenwich and New Haven, CT)

Search Committee Yale Cardiac Surgery, Aortic Institute at Yale New Haven (Prior) Prior Member: Dean’s Advisory Council on Yale Climate, Yale School of Medicine

Prior Preceptor Mentored internship for Grace Baldwin (CMO office and Aortic Institute)

– Ms. Baldwin is now attending Harvard Medical School

# PHILANTHROPIC EFFORTS and CONTRIBUTIONS

* Received $1,500.000 million dollars for Philanthropic Grant (2018-present time) to enhance works related to Physician Wellness and Burnout efforts at Yale Medical School and Yale New Haven Hospital (Alexa Daitch Foundational Grant)
* Received $300,000 dollar Philanthropic Grant (2018- present time) Foundational Grant for Aortic Institute at Yale / Yale New Hospital (Blaise and Sharon Masone Foundational Grant)
* Actively helping coordinate a major philanthropic donation for Neurosciences / Parkinson’s efforts at YNHH / Yale Medical School (ongoing efforts) (Stephen and Denise Adams Foundation). Initial $ 2 Million funding approved in July 2020 and will help recruitment of Neurology Faculty at Yale.
* Founded Annual Yale Masone Foundation Aortic Institute Endowed Lectureship (2018 - present time). Inaugural speaker (2018) was Valentin Fuster, MD (prior President of American Heart Association and American College of Cardiology); 2019 speakers included John Elefteriades, MD and myself. 2020 Lectureship deferred due to COVID –will be rescheduled
* Received $100,000 grant support (from YNHH Med Executive Finance Committee) to create and chair pilot Med Rewards Program (Time Banking System) at YNHH. Ongoing pilot project (2019-2020) involving Medical Executive Committee members .
* Received $25,000 for Ken Sperling Foundational Grant to raise educational awareness regarding Health Care and Medical Economics issues to Yale Medical students, and YNHH Residents and Fellows. Grant support by Sperling Family Foundation (issued with help and efforts from Jaime Gerber, MD). Inaugural Foundational Yale Medical Rounds to be held this December (2020) (Inaugural speaker: Thomas Balcezak, M.D., current Chief Clinical Officer at YNHH)
* Helped raise $250,000 cash-equivalent (collaborative effort between Yale University, YNHH, World Central Kitchen (Jose Andres) and Frontline Foods. Support and funds raised during height of COVID-19 pandemic (2020). Philanthropic support provided nearly 26,000 free meals to our frontline Healthcare MDs (Residents/Fellows/Attendings) as well as Nursing colleagues at YNHH. This effort also helped provide support for our local New Haven restaurant Community
* Received $10,000 (2019) philanthropic funding to establish Michael DiScala Foundation for Physician Wellness efforts at Yale New Haven Hospital
* Received $25,000 philanthropic gift for Yale Aortic Institute (from Joseph and Sandra Natarelli)
* Received $10,000 philanthropic gift from Leonard DiNardo for Physician Wellness efforts at Yale New Haven Hospital(2019)
* (Summary: Have helped raise nearly $4 million dollars for philanthropic contributions to YSM/YNHHS)